Guerbet leads entry into UK market with magnetic resonance imaging (MRI) agents
This article was originally published in Clinica
Executive Summary
French contrast agent manufacturer Guerbet has formed a UK subsidiary through which it will sell products directly to the market. The London-based operation, which will be headed by Francois Gary, will start up in the autumn and will initially sell MRI agents, Gullan Agerbak, director of the company's international subsidiaries division, told Clinica at the Rontgen Centenary congress in Birmingham last week.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.